Clinical trials: mRNA Vaccine
Respiratory Syncytial Virus
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age.
- Trial name
- NCT06060457
- Testing
- mRNA-1345, Fluzone HD
- Where
- 34 sites in United States
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups.
- Trial name
- NCT05373472
- Testing
- COVID-19 mRNA vaccine
- Where
- 3 sites in China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
SARS-CoV-2
Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants
An Open-Label, Phase 1 Clinical Study to Determine the Safety and Preliminary Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)
- Trial name
- NCT05599802
- Testing
- SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster
This is a randomized, phase Ⅱ, single-blind, randomized, parallel-group controlled clinical trial. The study plans to enroll subjects who have completed homologous primary vaccination with either inactivated or mRNA or Viral…
- Trial name
- NCT05465902
- Testing
- Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated, mRNA COVID-19 vaccine (Moderna)
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Influenza, Human
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and…
- Trial name
- NCT07204964
- Testing
- Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A)
- Where
- 17 sites in United States, Belgium
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
This study is a phase Ⅱ clinical trial to evaluate the safety and immunogenicity of SCTV01E-2 in people of different ages who had been vaccinated with COVID-19 vaccines.
- Trial name
- NCT05933512
- Testing
- SCTV01E-2, SCTV01E
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Respiratory Syncytial Virus Infections
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
The study will evaluate the safety, tolerability, and immunogenicity of 3 dose levels of IN006 in healthy adults aged 18 Years and Above; of a revaccination of IN006 given approximately 12 months after the initial vaccination in…
- Trial name
- NCT06645665
- Testing
- Bivalent RSV Vaccine (IN006)
- Where
- 2 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Lyme Disease
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
- Trial name
- NCT05975099
- Testing
- mRNA-1975, mRNA-1982
- Where
- 20 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Clinical Trial of SARS-CoV-2 mRNA Vaccine in China
This study is a phase I clinical trial. The investigators intent to evaluate the safety, tolerability and preliminary immunogenicity of SARS-CoV-2 mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over.
- Trial name
- NCT05364047
- Testing
- Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009
- Where
- 3 sites in China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Chlamydia Trachomatis Immunization
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia…
- Trial name
- NCT06891417
- Testing
- Chlamydia mRNA Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19 Vaccines
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age.
- Trial name
- NCT07730450
- Testing
- BNT162b2 Vaccine, Tdap Vaccine
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China
- Trial name
- NCT05547243
- Testing
- SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2, Influenza
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose…
- Trial name
- NCT05827926
- Testing
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2
- Where
- 69 sites in United States
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Genital Herpes
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
- Trial name
- NCT07330440
- Testing
- Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory…
- Trial name
- NCT06585241
- Testing
- mRNA-1273 Variant-containing Formulation
- Where
- 6 sites in United States
- Volunteers
- 1,144 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine.
- Trial name
- NCT06680375
- Testing
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA
- Where
- 9 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
- Trial name
- NCT07808697
- Testing
- mRNA-1283, mRNA-1273
- Where
- 31 sites in United States, Argentina and 4 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Human
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA)…
- Trial name
- NCT06431607
- Testing
- F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH
- Where
- 18 sites in United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5.
- Trial name
- COVID-19 (NCT05973006)
- Testing
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Where
- 20 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax